As vaccine makers tackle SARS-CoV-2 variants, WHO’s Chief Scientist feels it’s important to continue immunization programs with existing vaccines. Meanwhile, the rollouts mean the safety and efficacy landscape is set to change, said participants at a recent meet

South Africa recently decided against using AstraZeneca partner Serum Institute’s vaccine for its immunization program, given its low efficacy against the B.1.351 strain. However, certain vaccines have shown higher efficacy. Is this a sign that newer strains of SARS-CoV-2 could upset supply deals and revenue projections for some vaccines?

Experts discuss the complexities of pursuing compensation for COVID-19 vaccine-related injuries in India. Is there a case for ‘absolute liability’ for all injuries related to the two fast-tracked vaccines currently available, or alternatively a no-fault compensation program?

Multiple COVID-19 vaccines, including from RDIF and Novavax, could get accelerated approvals in India in the first half of calendar 2021, expanding the range at the country’s disposal. J&J's vaccine is expected to follow although it still hasn’t begun local trials, while Pfizer has temporarily withdrawn an application.